company has not made many significant external investments, excluding the recent $2.6 billion acquisition of Human Genome Sciences , which appears to be a fair value for the firm. Also, many of the legal claims that the company has settled
LONDON, Nov 1 (Reuters) - GlaxoSmithKline Plc : * Temporary increase in conversion rate for human genome sciences 3 percent
containment initiatives are falling a bit behind our forecasts. While the company had to absorb some costs from the Human Genome Sciences acquisition, marketing and administrative costs as a percentage of sales were up 200 basis points year over
By Cris Frangold : GlaxoSmithKline ( GSK ) reported relatively flat revenues for the second quarter of around $10.2 billion, which is a 2% decline on a year-on-year basis. Operating profit was over $2.7 billion. For the first six months of the fiscal year, sales at around $20.7 billion were also ...
matter to rest, as it has reached an agreement to acquire Human Genome Sciences . This brings several new drugs to the company in areas ..... and 2.7% over the next two quarters, respectively. Human Genome Sciences was trading around $14 at the time of the acquisition
By Cris Frangold : AstraZeneca ( AZN ) has been struggling a little bit to get high sales numbers out of its key heart drug Brilinta, but that may be starting to change. Moving forward with studies and gaining further recommendations will certainly help incentivize people to prescribe and use the
By Income Hunter : The recent acquisition of Human Genome Sciences , I nc. ( HGSI ), alongside the abundance of products in Phase III and regulatory review stages, exemplifies the success of GlaxoSmithKli ne
By Osman Gulseven : Amarin ( AMRN ), an Ireland-based company, is primarily focused on the development and commercialization of therapeutics to improve cardiovascular health. Amarin recently got approval for its drug Vascepa on July 27, 2012, which is useful for reducing levels of blood fat; ...
By Markus Aarnio : When insiders buy shares on the open market, their companies are usually undervalued. Corporate insiders often have the inside track on their companies' prospects. Insiders probably wouldn't risk investing too much of their own money into their own companies unless they thought
By Kapitall : Interested in the high-growth prospects of the healthcare sector? For a closer look at some promising healthcare names, we ran a screen. We began by screening the healthcare sector for stocks with positive market sentiment, rallying above their 20-day, 50-day, and 200-day moving ...